DOCOSANOL (doc'os-a-nol) Abreva Classifications: antiviral-like; Therapeutic: antiviral-like Pregnancy Category: C |
10% cream
Docosanol inhibits viral replication by interfering with the early intracellular events surrounding viral entry into target cells. It exhibits preferential activity against lipid-enveloped viruses that use fusion mechanisms for entry into target cells. This renders such target cells less susceptible to viral fusion or entry.
Believed to exert its antiviral effect by inhibiting fusion of the HSV (herpesvirus) envelope with the human cell plasma membrane, therefore making it difficult for the virus to enter the cell and replicate.
Treatment of herpes simplex infections of the face and lips (i.e., cold sores).
Hypersensitivity to docosanol or any of the inactive ingredients in the ointment; immunosuppressant patients; pregnancy (category C); lactation.
Safety and efficacy in children are not established.
Herpes Simplex Infections Adult: Topical Apply to lesions 5 times/d for up to 10 d, starting at onset of symptoms |
Assessment & Drug Effects
Patient & Family Education